Manufacturer offers money-back guarantee on BPH drug

Article

Sanofi-Synthelabo Inc. has introduced a money-back guarantee program for BPH patients not satisfied after taking extended-release alfuzosin hydrochloride (Uroxatral) as directed by their physician.

Sanofi-Synthelabo Inc. has introduced a money-back guarantee program for BPH patients not satisfied after taking extended-release alfuzosin hydrochloride (Uroxatral) as directed by their physician.

The guarantee program provides up to a 30-day reimbursement of the patient's out-of-pocket prescription cost if the patient's urologist determines that alfuzosin was not right for him. The company will also reimburse costs if the patient experiences side effects including, but not limited to, ejaculatory or erectile dysfunction.

Alfuzosin is a uroselective alpha-blocker.

Related Videos
Related Content
Pivotal data for lumasiran in PH1 published in NEJM

Pivotal data for lumasiran in PH1 published in NEJM

April 1st 2021
Article

The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.

Nedosiran explored in primary hyperoxaluria type 3

Nedosiran explored in primary hyperoxaluria type 3

February 26th 2021
Article

The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria.

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

February 9th 2021
Article

FDA new drug application filing expected by the end of 2021.

Site Logo

FDA approves androgen inhibitor for metastatic PCa

September 12th 2012
Article

The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).

Site Logo

Blood test could guide treatment for kidney cancer

August 29th 2012
Article

A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to physicians at Duke Cancer Institute, Durham, NC.

Site Logo

BCG for bladder cancer in short supply

August 22nd 2012
Article

Due to manufacturing issues, a formulation of the bladder cancer treatment bacillus Calmette-Guérin is currently unavailable from one manufacturer.

© 2024 MJH Life Sciences

All rights reserved.